Amgen: Migraine Disorders trials

The registry lists 24 Migraine Disorders studies with Amgen as lead sponsor. 1 are open to participants now and 19 have results posted.

Phase 1 7Phase 2 5Phase 3 5Phase 4 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Aimovig Pregnancy Exposure RegistryRecruitingNCT06150781
• A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With MigraineCompletedNCT04825678Phase 4Results posted
• Biomarker and Genetic Predictors of Erenumab Treatment ResponseCompletedNCT04265755Phase 4Results posted
• Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigraineCompletedNCT04252742Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheCompletedNCT03971071Phase 4Results posted
• Study of Sustained Benefit of AMG334 in Adult Episodic Migraine PatientsCompletedNCT03927144Phase 4Results posted
• Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic MigraineTerminatedNCT03912337Phase 4Results posted
• A Controlled Trial of Erenumab in Migraine PreventionCompletedNCT03812224Phase 3Results posted
• AMG 334 20160172 Pediatric Migraine PK Study.CompletedNCT03499119Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine PreventionCompletedNCT03238781Phase 2Results posted
• Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy FemalesCompletedNCT02792517Phase 1Results posted
• A Safety and Efficacy Study to Evaluate AMG 334 in Migraine PreventionCompletedNCT02630459Phase 2Results posted
• To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine PatientsCompletedNCT02542605Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine PreventionCompletedNCT02483585Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine PreventionCompletedNCT02456740Phase 3Results posted
• A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.CompletedNCT02174861Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine PreventionCompletedNCT02066415Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine PreventionCompletedNCT01952574Phase 2Results posted
• Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine PatientsCompletedNCT01723514Phase 1Results posted
• Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine PatientsCompletedNCT01688739Phase 1Results posted
• Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineActive, not recruitingNCT03836040Phase 3
• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineCompletedNCT03832998Phase 3
• Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine SubjectsTerminatedNCT02132429Phase 1
• Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With MigrainesCompletedNCT01953341Phase 1